So far, the maybe greatest patient benefit of immunomodulatory treatment was achieved by IL-1 inhibition (CANTOS trial) in previous MI patients with raised inflammatory profiles, thus at greater risk of developing subsequent MIs or HF. This evidence concerns the gene IL1A and myocardial infarction.